🔥 We’ve hit 50% recruitment in the #COMBATtrial!.Huge thanks to all involved!💙.@RautouE @ef_clif @hospitalclinic @LiverIcu @UniklinikAachen @Unibo @Zac_MD @DrAAlbillos @unito @VHIR_ @APHP @UK_Muenster @MEDB_LAB @UschnerFrank @rajmookerjee . #LiverTwitter #ACLF #ClinicalTrials

🎥 New keynote online!.Prof. Richard Moreau, Director of @ef_clif, explores immune dysfunction in AD & #ACLF and suggests a common mechanism behind inflammation & immune deficiency. Watch now 👉 #LiverTwitter #Hepatology

🎉 Exciting news: We’ve surpassed 500 followers on @LinkedIn!.Follow us there for updates on trials, science, and more 👉 #ClinicalResearch #DECISIONproject

Consider joining this event by A-TANGO and @Crowdhelix! ."Industrial Perspective on Drug Development Challenges for Clinical Trials". 📅 4th June 2025.🕚 11:00 am CEST / 🕙 10:00 am BST.You can register via this link:

It’s #ClinicalTrialsDay! At DECISION, we’re proud of our COMBAT & PROSPECT trials advancing care in decompensated cirrhosis. 💡COMBAT Q&A videos in multiple languages help engage patients ➡️ Thanks to all who make our trials possible! #LiverResearch

Clinical trajectories of patients with cirrhosis and ascites receiving long-term albumin.#POSTER SAT-145-YI by Enrico Pompili (UNIBO) proposes a personalized management approach for patients w. cirrhosis &ascites, based on real-world data from long-term albumin therapy. #EASL2025

Impact of diabetes mellitus on clinical outcomes in patients with acutely decompensated cirrhosis . #E_POSTER by Mimma Bonomo (UNITO) explores how coexisting diabetes mellitus affects prognosis in patients hospitalized with acute decompensation of cirrhosis #EASL2025 @EASLnews

🦠The recovery failure of fecal microbiota diversity in patients after liver transplant is associated with a complicated postoperative course. #POSTER SAT-518 by Maike Rebecca Pollmanns from @UniklinikAachen at #EASL2025. @tony_bruns.@EASLnews

🧪 Acute kidney disease in acutely decompensated cirrhosis: impact on clinical outcomes.#POSTER SAT-122-YI by @AlbCalle (UNITO) examines how acute kidney disease affects outcomes in patients w. acutely decompensated cirrhosis. 📅 Presented at #EASLCongress | #EASL2025 @EASLnews

@RautouE.

❤️Cardiac performance is impaired in patients with proven alcohol-related hepatitis and predicts 3-month mortality in this patient population . #POSTER SAT-503-YI by Pierre-Emmanuel Rautou (@Inserm, APHP, EF CLIF) . 📅 Presented at the #EASLCongress | #EASL2025.@EASLnews

Back in the Abstract Session: Theresa Wirtz presents her scRNA-seq work on monocyte subsets and ACLF risk. @UniklinikAachen.@tony_bruns @EASLnews . #Cirrhosis #ACLF #EASL2025

Estefania Huergo presents methylation data in AD patients, selected as best Young Investigator abstract in Basic Science at #EASL2025 - Congrats! 🎉.@navarrabiomed @EASLnews .#Epigenetics #LiverResearch #EASL2025

Javier Fernandez (FCRB) is giving the hepatologist perspective on management of MDR infections in cirrhosis as part of the EASL/ESCMID Symposium: MDR infections - a challenge in decompensated cirrhosis at #EASL2025. #LiverDisease #Cirrhosis #Hepatology.@EASLnews

Is the etiological work-up of #PSVD a one-size-fits-all?. DECISION consortium member Lucile Moga from APHP takes part in EASL/ VALDIG's session on "Do's and Don'ts in the management of Porto-Sinusoidal Vascular Disease". #EASLCongress #EASL2025 #LiverResearch .@EASLnews

How do you build & lead a successful research team?.The next generation of PIs learned straight from the best in today's workshop “How to Start a Research Group: From Postdoc to PI" as @RautouE shared practical insights on building & maintaining a high-performing team. #EASL2025

DECISION consortium member Sophie Lotersztajn from the French research institute @Inserm at a late-afternoon abstract session on Friday, May 9th 2025, at #EASLCongress in Amsterdam, the Netherlands, about #fibrosis, #hepatocyte and #liver #regeneration. 🩺

Congrats on presenting your poster in the Track Hub 4 this afternoon, Maike! 🙌

🔬 #POSTER FRI-222 by Thierry Gustot (EF CLIF) proposes one-week criteria to assess the appropriateness of continuing intensive care in ACLF patients who are not candidates for liver transplantation. #EASL2025 @EASLnews @ef_clif

📊 Fibroblast growth factor 19 (FGF-19) predicts transplant free-survival in critically ill patients with acute-onchronic liver failure. #POSTER FRI-199 by Maike Rebecca Pollmanns (UKA) . Presented at the #EASLCongress | #EASL2025.@EASLnews.@UniklinikAachen